不同联合化疗方案治疗晚期非小细胞肺癌的临床观察

Comparison of Effects of Three Chemotherapy Regimens for Advanced Non-Small Cell Lung Cancer

背景与目的:已证实以铂类为基础的联合化疗对晚期非小细胞肺癌患者有益,但近十年来对化疗方案选择仍有争论。本研究观察比较MIP方案(MMC+IFO+DDP)、TP方案(泰素+DDP)和DP方案(泰索帝+DDP)联合治疗晚期非小细胞肺癌的近期疗效和耐受性。方法∶92例晚期非小细胞肺癌分为3组,分别接受3种不同化疗方案治疗,MIP组32例,TP组30例,DP组30例;除DP组Ⅳ期病例较多并有复治病人外,3组病人其它因素均具有可比性。结果:MIP组有效率为43.8%,中位生存期为11个月,1年生存率为46%;TP组有效率为40.0%,中位生存期为10个月,1年生存率为40%;DP组有效率为46.7%,中位生存期为12个月,1年生存率为50%。3组有效率相似,主要不良反应为骨髓抑制、恶心呕吐和脱发。结论:本研究表明,3种化疗方案均对晚期非小细胞肺癌有相似的疗效,不良反应可耐受,但泰索帝每周方案骨髓抑制相对较少。

Background & Objective: The platinum combination chemotherapy has been proved to be benefit to the patients with advanced non small cell lung cancer (NSCLC), but the suitable regimen of chemotherapy has been much debated during the last decade. This study was designed to compare MIP regimen [mitomycin+ifosfamid+cisplatin],TP regimen [Taxol+ cisplatin],and DP regimen [docetaxel+cisplatin] and to evaluate the efficacy of the three regimens in patients with advanced NSCLC. Methods:Ninety two patients were enrolled in this study, 32 for MIP, 30 for TP,and 30 for DP.The characteristics of patients were comparable except there were more stage Ⅳ patients and second chemotherapy patients in DP group. Results: For MIP, TP, and DP groups, the objective response rates were 43.8%,40%,and 46.7%,respectively; the median duration of survival were 11, 10,and 12 months respectively; the 1 year survival rate were 46%,40%,and 50%,respectively.The major toxicities were bone marrow suppression,nausea,vomiting,and alopecia. Conclusions: MIP, TP, and DP regimens are effective and safe chemotherapy protocols for the treatment of advanced NSCLC patients.